Study Groups

This is an extension of a planned dihydroartemisinin-piperaquine (DP) Safety Study Group, which aims to consider the effect of HIV disease and co-administration of widely-used antiretroviral (ARVs) on the safety of DP. Due to a lack of available DP studies, the individual patient data (IPD) meta-analysis will have greater public health value when these results were compared to other ACTs.

Development of statistical methods to infer the relationship between the percentage of resistant infections, parasite clearance half-life and the proportion of treated individuals still positive on days one, two and three of treatment

Modelling the protective effect of Artesunate-Amodiaquine (AS-AQ)

A pooled analysis to assess the post-treatment prophylactic effect of artesunate-amodiaquine (AS-AQ). The group is quantifying the duration of post-treatment prophylaxis mediated by AS-AQ and how it depends on host factors such as .

The Study Group closed in January 2014. The AS-AQ Post-Treatment Prophylaxis Study Group manuscript is under review at BMC Medicine. 

Assessing the efficacy of a range of antimalarials used for the treatment of P. falciparum malaria in all trimesters of pregnancy in Africa and Asia

The MiP Treatment Efficacy Study Group was formed in July 2016, with a call to interested researchers with relevant data sets.

A pooled analysis assessing the effect of mg/kg dosing strategies on the risk of treatment failure in patients treated with the currently recommended dose of artesunate-mefloquine (AS-MQ).

Research groups with relevant data have been contacted with data collection and curation still ongoing. Analysis will start in late 2016 and drafting publication in expected in 2018.

Baseline information on parasitological response to ACTs in Asia

A pooled analysis to assess the baseline early parasitological response after artemisinin combination therapy (ACT) treatment in Asia. The analysis compiles the day 3 parasite positivity rates (PPR) in patients with uncomplicated Plasmodium falciparum malaria enrolled in ACT clinical efficacy trials conducted in Asia.

Data gathering and curation has started. Data meeting the inclusion criteria has already been collected and standardised from over 12,000 patients. Data analysis will start April 2015 with a manuscript schedules for submission and publication by December 2015.